|
1
|
Mostafa ME, Erbarut-Seven I, Pehlivanoglu
B and Adsay V: Pathologic classification of ‘pancreatic cancers’:
Current concepts and challenges. Chin Clin Oncol. 6:592017.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Moyer MT and Gaffney RR: Pancreatic
adenocarcinoma. N Engl J Med. 371:21402014.PubMed/NCBI
|
|
3
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bukki J: Pancreatic adenocarcinoma. N Engl
J Med. 371:2139–2140. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kuhlmann KF, de Castro SM, Wesseling JG,
ten Kate FJ, Offerhaus GJ, Busch OR, van Gulik TM, Obertop H and
Gouma DJ: Surgical treatment of pancreatic adenocarcinoma; actual
survival and prognostic factors in 343 patients. Eur J Cancer.
40:549–558. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Parker SL, Tong T, Bolden S and Wingo PA:
Cancer statistics, 1997. CA Cancer J Clin. 47:5–27. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Seufferlein T, Porzner M, Becker T, Budach
V, Ceyhan G, Esposito I, Fietkau R, Follmann M, Friess H, Galle P,
et al: S3-guideline exocrine pancreatic cancer. Z Gastroenterol.
51:1395–1440. 2013.(In German). PubMed/NCBI
|
|
8
|
Erkan M, Michalski CW, Rieder S,
Reiser-Erkan C, Abiatari I, Kolb A, Giese NA, Esposito I, Friess H
and Kleeff J: The activated stroma index is a novel and independent
prognostic marker in pancreatic ductal adenocarcinoma. Clin
Gastroenterol Hepatol. 6:1155–1161. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hidalgo M: Pancreatic cancer. N Engl J
Med. 362:1605–1617. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Erkan M, Adler G, Apte MV, Bachem MG,
Buchholz M, Detlefsen S, Esposito I, Friess H, Gress TM, Habisch
HJ, et al: StellaTUM: Current consensus and discussion on
pancreatic stellate cell research. Gut. 61:172–178. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Apte MV, Park S, Phillips PA, Santucci N,
Goldstein D, Kumar RK, Ramm GA, Buchler M, Friess H, McCarroll JA,
et al: Desmoplastic reaction in pancreatic cancer: Role of
pancreatic stellate cells. Pancreas. 29:179–187. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bochet L, Lehuede C, Dauvillier S, Wang
YY, Dirat B, Laurent V, Dray C, Guiet R, Maridonneau-Parini I, Le
Gonidec S, et al: Adipocyte-derived fibroblasts promote tumor
progression and contribute to the desmoplastic reaction in breast
cancer. Cancer Res. 73:5657–5668. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Von Hoff DD, Ervin T, Arena FP, Chiorean
EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et
al: Increased survival in pancreatic cancer with nab-paclitaxel
plus gemcitabine. N Engl J Med. 369:1691–1703. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Xiao AY, Tan ML, Wu LM, Asrani VM, Windsor
JA, Yadav D and Petrov MS: Global incidence and mortality of
pancreatic diseases: A systematic review, meta-analysis, and
meta-regression of population-based cohort studies. Lancet
Gastroenterol Hepatol. 1:45–55. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Berlin JD, Catalano P, Thomas JP, Kugler
JW, Haller DG and Benson AB III: Phase III study of gemcitabine in
combination with fluorouracil versus gemcitabine alone in patients
with advanced pancreatic carcinoma: Eastern Cooperative Oncology
Group Trial E2297. J Clin Oncol. 20:3270–3275. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rocha Lima CM, Green MR, Rotche R, Miller
WH Jr, Jeffrey GM, Cisar LA, Morganti A, Orlando N, Gruia G and
Miller LL: Irinotecan plus gemcitabine results in no survival
advantage compared with gemcitabine monotherapy in patients with
locally advanced or metastatic pancreatic cancer despite increased
tumor response rate. J Clin Oncol. 22:3776–3783. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hessmann E, Schneider G, Ellenrieder V and
Siveke JT: MYC in pancreatic cancer: Novel mechanistic insights and
their translation into therapeutic strategies. Oncogene.
35:1609–1618. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sears RC: The life cycle of C-MYC: From
synthesis to degradation. Cell Cycle. 3:1133–1137. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Dang CV, O'Donnell KA, Zeller KI, Nguyen
T, Osthus RC and Li F: The c-MYC target gene network. Semin Cancer
Biol. 16:253–264. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Slack GW and Gascoyne RD: MYC and
aggressive B-cell lymphomas. Adv Anat Pathol. 18:219–228. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Dalla-Favera R, Bregni M, Erikson J,
Patterson D, Gallo RC and Croce CM: Human c-MYC onc gene is located
on the region of chromosome 8 that is translocated in Burkitt
lymphoma cells. Proc Natl Acad Sci USA. 79:7824–7827. 1982.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sewastianik T, Prochorec-Sobieszek M,
Chapuy B and Juszczynski P: MYC deregulation in lymphoid tumors:
Molecular mechanisms, clinical consequences and therapeutic
implications. Biochim Biophys Acta. 1846:457–467. 2014.PubMed/NCBI
|
|
24
|
La Rosa S, Bernasconi B, Vanoli A, Sciarra
A, Notohara K, Albarello L, Casnedi S, Billo P, Zhang L, Tibiletti
MG and Sessa F: c-MYC amplification and c-myc protein expression in
pancreatic acinar cell carcinomas. New insights into the molecular
signature of these rare cancers. Virchows Arch. 473:435–441. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Johnson KR, Cook SA and Davisson MT:
Chromosomal localization of the murine gene and two related
sequences encoding high-mobility-group I and Y proteins. Genomics.
12:503–509. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Fusco A and Fedele M: Roles of HMGA
proteins in cancer. Nat Rev Cancer. 7:899–910. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Reeves R and Nissen MS: The
A.T-DNA-binding domain of mammalian high mobility group I
chromosomal proteins. A novel peptide motif for recognizing DNA
structure. J Biol Chem. 265:8573–8582. 1990.PubMed/NCBI
|
|
28
|
Sgarra R, Zammitti S, Lo Sardo A, Maurizio
E, Arnoldo L, Pegoraro S, Giancotti V and Manfioletti G: HMGA
molecular network: From transcriptional regulation to chromatin
remodeling. Biochim Biophys Acta. 1799:37–47. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Fedele M and Fusco A: HMGA and cancer.
Biochim Biophys Acta. 1799:48–54. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wu J and Wei JJ: HMGA2 and high-grade
serous ovarian carcinoma. J Mol Med (Berl). 91:1155–1165. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chiappetta G, Avantaggiato V, Visconti R,
Fedele M, Battista S, Trapasso F, Merciai BM, Fidanza V, Giancotti
V, Santoro M, et al: High level expression of the HMGI (Y) gene
during embryonic development. Oncogene. 13:2439–2446.
1996.PubMed/NCBI
|
|
32
|
Chang HY, Ye SP, Pan SL, Kuo TT, Liu BC,
Chen YL and Huang TC: Overexpression of miR-194 reverses
HMGA2-driven signatures in colorectal cancer. Theranostics.
7:3889–3900. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hontecillas-Prieto L, Garcia-Dominguez DJ,
Garcia-Mejias R, Ramirez-Villar GL, Saez C and de Alava E: HMGA2
overexpression predicts relapse susceptibility of blastemal Wilms
tumor patients. Oncotarget. 8:115290–115303. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hristov AC, Cope L, Reyes MD, Singh M,
Iacobuzio-Donahue C, Maitra A and Resar LM: HMGA2 protein
expression correlates with lymph node metastasis and increased
tumor grade in pancreatic ductal adenocarcinoma. Mod Pathol.
22:43–49. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Allen PJ, Kuk D, Castillo CF, Basturk O,
Wolfgang CL, Cameron JL, Lillemoe KD, Ferrone CR, Morales-Oyarvide
V, He J, et al: Multi-institutional validation study of the
American Joint Commission on Cancer (8th Edition) Changes for T and
N Staging in patients with pancreatic adenocarcinoma. Ann Surg.
265:185–191. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Rieser CJ, Zenati M, Hamad A, Al Abbas AI,
Bahary N, Zureikat AH, Zeh HJ III and Hogg ME: CA19-9 on
postoperative surveillance in pancreatic ductal adenocarcinoma:
Predicting recurrence and changing prognosis over time. Ann Surg
Oncol. 25:3483–3491. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Chang HJ, Yoo BC, Kim SW, Lee BL and Kim
WH: Significance of PML and p53 protein as molecular prognostic
markers of gallbladder carcinomas. Pathol Oncol Res. 13:326–335.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Erkan M, Reiser-Erkan C, Michalski CW,
Deucker S, Sauliunaite D, Streit S, Esposito I, Friess H and Kleeff
J: Cancer-stellate cell interactions perpetuate the
hypoxia-fibrosis cycle in pancreatic ductal adenocarcinoma.
Neoplasia. 11:497–508. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lonardo E, Frias-Aldeguer J, Hermann PC
and Heeschen C: Pancreatic stellate cells form a niche for cancer
stem cells and promote their self-renewal and invasiveness. Cell
Cycle. 11:1282–1290. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
40
|
Van den Broeck A, Gremeaux L, Topal B and
Vankelecom H: Human pancreatic adenocarcinoma contains a side
population resistant to gemcitabine. BMC Cancer. 12:3542012.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Morris JP IV, Wang SC and Hebrok M: KRAS,
Hedgehog, Wnt and the twisted developmental biology of pancreatic
ductal adenocarcinoma. Nat Rev Cancer. 10:683–695. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Chung V, McDonough S, Philip PA, Cardin D,
Wang-Gillam A, Hui L, Tejani MA, Seery TE, Dy IA, Al Baghdadi T, et
al: Effect of Selumetinib and MK-2206 vs Oxaliplatin and
fluorouracil in patients with metastatic pancreatic cancer after
prior therapy: SWOG S1115 study randomized clinical trial. JAMA
Oncol. 3:516–522. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Salomon DS, Brandt R, Ciardiello F and
Normanno N: Epidermal growth factor-related peptides and their
receptors in human malignancies. Crit Rev Oncol Hematol.
19:183–232. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Cohenuram M and Saif MW: Epidermal growth
factor receptor inhibition strategies in pancreatic cancer: Past,
present and the future. JOP. 8:4–15. 2007.PubMed/NCBI
|
|
45
|
Ioannou N, Dalgleish AG, Seddon AM,
Mackintosh D, Guertler U, Solca F and Modjtahedi H: Anti-tumour
activity of afatinib, an irreversible ErbB family blocker, in human
pancreatic tumour cells. Br J Cancer. 105:1554–1562. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Liles JS, Arnoletti JP, Kossenkov AV,
Mikhaylina A, Frost AR, Kulesza P, Heslin MJ and Frolov A:
Targeting ErbB3-mediated stromal-epithelial interactions in
pancreatic ductal adenocarcinoma. Br J Cancer. 105:523–533. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Moore MJ, Goldstein D, Hamm J, Figer A,
Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, et al:
Erlotinib plus gemcitabine compared with gemcitabine alone in
patients with advanced pancreatic cancer: A phase III trial of the
National Cancer Institute of Canada Clinical Trials Group. J Clin
Oncol. 25:1960–1966. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Chua YJ and Zalcberg JR: Pancreatic
cancer-is the wall crumbling? Ann Oncol. 19:1224–1230. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Dang CV: c-MYC target genes involved in
cell growth, apoptosis, and metabolism. Mol Cell Biol. 19:1–11.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Xu J, Chen Y and Olopade OI: MYC and
breast cancer. Genes Cancer. 1:629–640. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Nesbit CE, Tersak JM and Prochownik EV:
MYC oncogenes and human neoplastic disease. Oncogene. 18:3004–3016.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Di Cello F, Hillion J, Hristov A, Wood LJ,
Mukherjee M, Schuldenfrei A, Kowalski J, Bhattacharya R, Ashfaq R
and Resar LM: HMGA2 participates in transformation in human lung
cancer. Mol Cancer Res. 6:743–750. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Ozturk N, Singh I, Mehta A, Braun T and
Barreto G: HMGA proteins as modulators of chromatin structure
during transcriptional activation. Front Cell Dev Biol. 2:52014.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Pallante P, Sepe R, Puca F and Fusco A:
High mobility group a proteins as tumor markers. Front Med
(Lausanne). 2:152015.PubMed/NCBI
|
|
55
|
Thuault S, Valcourt U, Petersen M,
Manfioletti G, Heldin CH and Moustakas A: Transforming growth
factor-beta employs HMGA2 to elicit epithelial-mesenchymal
transition. J Cell Biol. 174:175–183. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Kaur H, Ali SZ, Huey L, Hütt-Cabezas M,
Taylor I, Mao XG, Weingart M, Chu Q, Rodriguez FJ, Eberhart CG and
Raabe EH: The transcriptional modulator HMGA2 promotes stemness and
tumorigenicity in glioblastoma. Cancer Lett. 377:55–64. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Madison BB, Jeganathan AN, Mizuno R,
Winslow MM, Castells A, Cuatrecasas M and Rustgi AK: Let-7
represses carcinogenesis and a stem cell phenotype in the intestine
via regulation of Hmga2. PLoS Genet. 11:e10054082015. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Piscuoglio S, Zlobec I, Pallante P, Sepe
R, Esposito F, Zimmermann A, Diamantis I, Terracciano L, Fusco A
and Karamitopoulou E: HMGA1 and HMGA2 protein expression correlates
with advanced tumour grade and lymph node metastasis in pancreatic
adenocarcinoma. Histopathology. 60:397–404. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Sahai V, Kumar K, Knab LM, Chow CR, Raza
SS, Bentrem DJ, Ebine K and Munshi HG: BET bromodomain inhibitors
block growth of pancreatic cancer cells in three-dimensional
collagen. Mol Cancer Ther. 13:1907–1917. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Dangi-Garimella S, Sahai V, Ebine K, Kumar
K and Munshi HG: Three-dimensional collagen I promotes gemcitabine
resistance in vitro in pancreatic cancer cells through
HMGA2-dependent histone acetyltransferase expression. PLoS One.
8:e645662013. View Article : Google Scholar : PubMed/NCBI
|
